Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
NEW YORK, Aug. 08, 2017 -- According to a new research report “Dry Eye Syndrome Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Dry Eye Syndrome currently exhibits a pipeline with 50 drug candidates.
Browse Report Summary at: https://www.psmarketresearch.com/market-analysis/dry-eye-syndrome-therapeutics-pipeline-analysis
The study analyzed that the dry eye syndrome therapeutics pipeline comprises approximately 50 drug candidates in different stages of development.
According to the research findings, most of the drug candidates of dry eye syndrome pipeline are being developed to be administered by topical route.
InSite Vision (A Sun Pharmaceutical Industries Ltd. company) is using DuraSite technology platform for the development of their drug candidates for the treatment of dry eye syndrome. DuraSite is a drug delivery vehicle that stabilizes small molecules in a polymeric mucoadhesive matrix.
Make Enquiry Before Buying: https://www.psmarketresearch.com/send-enquiry?enquiry-url=dry-eye-syndrome-therapeutics-pipeline-analysis
The research found that various companies use natural sources for the development of dry eye syndrome therapeutics pipeline that includes, but not limited to, MC2 Therapeutics and RegeneRx Biopharmaceuticals, Inc.
Some of the other key players developing drugs for the treatment of dry eye syndrome include Ocular Therapeutix, Inc., LTT Bio-Pharma, HanAll BioPharma Co., Ltd. and others.
Browse Other Reports:
Lennox-Gastaut Syndrome Therapeutics Pipeline Analysis
Lennox-Gastaut Syndrome is a rare form of epilepsy that occurs in childhood and is characterized by seizures and intellectual disability. Adverse conditions such as injury to brain and its malformation, lack of oxygen to the new-born infants, infections of central nervous system and inherited metabolic or degenerative disorders are responsible for occurrence of Lennox-Gastaut Syndrome. Anti-epileptic medications are the main treatment option for Lennox-Gastaut Syndrome. The medication is often complicated in case of paediatric disorders as there is risk in development of new-born, due to which various research organizations are focussing on development of therapeutics of Lennox-Gastaut Syndrome.
Narcolepsy Therapeutics Pipeline Analysis
Narcolepsy is a disease that causes prolongation of extreme daytime sleepiness which can leads to muscle weakness and trouble sleeping at night. The complication associated with the disease are cataplexy, hallucinations and sleep paralysis. Due to these complication, the person is at increased risk of developing mental disorders such as schizophrenia. The environmental factors such as toxins that contains heavy metals, pesticides and weed killers and environmental tobacco smoke are thought to be the cause that narcolepsy therapeutic pipeline is expanding. Researchers have found that the disease can occur due to genetic abnormality, that can transfer from one generation to the next generation. There are various novel gene therapies which are under development for the treatment of Narcolepsy. Increasing number of road accidents causing brain injury, autoimmune disorders and fungal or bacterial infections are some of the key factors responsible for the growth of narcolepsy therapeutic pipeline.
https://www.psmarketresearch.com/market-analysis/narcolepsy-therapeutics-pipeline-analysis
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact:
Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: [email protected]
Web: https://www.psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook
